Journals / Ege Tıp Dergisi / 2019 / Cilt: 58 - Sayı: 0

The comparison of new biologic treatments in psoriatic arthritis

Psoriatik artritin tedavisinde yeni ilaçların karşılaştırması

Pages
48–50
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Given the heterogeneity PsA, the treatments should be tailored to individual cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Psoriatic arthritis (PsA) is characterized by a wide spectrum of articular and extra-articular clinical manifestations including peripheral arthritis, spondylitis, enthesitis, dactylitis, skin and eye involvement, and systemic features such as metabolic syndrome and cardiovascular ischemic disease.
📊
Key Findings & Data:The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations.
💡
Conclusion & Impact:Given the heterogeneity PsA, the treatments should be tailored to individual cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Psoriatic arthritis (PsA) is characterized by a wide spectrum of articular and extra-articular clinical manifestations including peripheral arthritis, spondylitis, enthesitis, dactylitis, skin and eye involvement, and systemic features such as metabolic syndrome and cardiovascular ischemic disease. The diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. Given the heterogeneity PsA, the treatments should be tailored to individual cases.

Özet

Psoriatik artrit (PsA), periferik artrit, spondilit, entezit, daktilit, deri ve göz tutulumu, metabolik sendrom ve kardiovasküler iskemik hastalıklar gibi sistemik özelliklerin olduğu artiküler ve ekstraartiküler klinik belirtilerle karakterize bir hastalıktır. Farklı klinik belirtileri olan bir hastalık olduğu için PsA’te klinik belirtilere göre farklı tedavi kombinasyonlarının saptanmasına ihtiyaç vardır. Heterojen bir hastalık olan PsA’te tedavi kişiselleştirilmelidir.

🔖

Cite This Article

ZİHNİ, F. Y. (2019). The comparison of new biologic treatments in psoriatic arthritis. Ege Tıp Dergisi, Cilt: 58 - Sayı: 0, 48–50. https://ajindex.com/articles/158341

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl 2):ii14-17
  2. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42(12):1460-8
  3. Lloyd P, Ryan C, Menter A. Psoriatic arhtitis: an update. Arthritis 2012;2012:1762982
  4. Arumugam R, McHugh NJ. Mortality and causes of death in psoriatic arthritis. J Rheumatol Suppl 2012;89:32-5
  5. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011(9783);377:2127–37
  6. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
  7. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74
  8. Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013;149:1180-5
  9. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: Treatment Recommendations for Psoriatic Arthritis 2015. Arthritis Rheumatol 2016;68(5):1060-71
  10. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499510
  11. Kristianslund EK, Fagerli KM, Lie E, et al. Real life effectiveness of TNF inhibitors in psoriatic arthritis: Are changing national policies on choice of TNF inhibitör reflected in response to treatment? EULAR 2017 FRI0490 Ann Rheum Dis 2017;76(Suppl 2):673-4
  12. Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 2014, 26:361-70
  13. Jørgensen TS, Dreyer L, Gudbjornsson B, et al. Prescription patterns of tumor necrosis factor inhibitör and ustekinumab in psoriatic arth